What Are Insulinotropic Polypeptides?
Insulinotropic polypeptides regulate insulin secretion in response to meal consumption (Hammoud, 2024). GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (Glucagon-Like Peptide-1) are the two most well-known insulinotropic polypeptides (Vilsbøll, 2003). These peptides belong to the incretin hormone family and play an important role in glucose metabolism by stimulating insulin release from pancreatic beta cells in a glucose-dependent manner (Seino, 2023)
K-cells in the small intestine secrete GIP, whereas L-cells in the lower intestine generate GLP-1 (Rehfeld, 2018). Both hormones stimulate insulin secretion, whereas GLP-1 slows stomach emptying and decreases hunger (Jalleh, 2024). GIP, on the other hand, regulates lipid metabolism and may promote fat storage (Sachs, 2024). Insulinotropic polypeptides have been targeted for therapeutic interventions due to their glucose-regulating properties, particularly in the management of diabetes and obesity.
One of the most recent developments in this field is retatrutide, a new triple agonist that targets GIP, GLP-1, and glucagon receptors (Jastreboff, 2023). In clinical trials, this medication shown potential weight loss and metabolic improvements (Lilly, 2023; Sanyal, 2024).
How Are Insulinotropic Polypeptides Biologically Regulated?
Dietary intake, metabolic condition, and hormone interactions all have a strong influence on insulinotropic polypeptide secretion and activity.
1. Nutrient Intake - Ingestion of carbs, lipids, and proteins causes the production of GIP and GLP-1. High-fat meals boost GIP production, while carbs largely promote GLP-1 release (Fukuda, 2021).
2. Glucose-Dependent Action - Unlike insulin, which can be produced in response to a variety of stimuli, GIP and GLP-1 only increase insulin release when blood glucose levels rise. This lowers the risk of hypoglycemia (Christensen, 2015).
3. Enzymatic Breakdown - The enzyme dipeptidyl peptidase-4 (DPP-4) rapidly degrades GIP and GLP-1, limiting its half-life. This has resulted in the creation of DPP-4 inhibitors, a type of diabetic drug that prolongs incretin action (Yin, 2022).
4. Receptor Interactions: GIP and GLP-1 activate their respective receptors on pancreatic beta cells (GIPR and GLP-1R), leading to increased insulin production (Zaïmia, 2023). However, GLP-1 has other effects, such as slowing stomach emptying and decreasing hunger, making it an important target for obesity therapy.
Retatrutide and Its Clinical Significance
Retatrutide is an investigational triple receptor agonist that targets the GIP, GLP-1, and glucagon receptors, presenting a novel approach to metabolic illness management. A 48-week phase 2 obesity study found significant weight reductions of 22.8% and 24.2% at 8 mg and 12 mg doses, respectively (Lilly, 2023) (Sanyal, 2024).
A substudy of metabolic dysfunction-associated steatotic liver disease (MASLD) discovered that retatrutide significantly reduced liver fat (Kaur, 2024). Participants with at least 10% liver fat at baseline received once-weekly subcutaneous injections of retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo. After 24 weeks, liver fat reductions were (Lilly, 2023) (Sanyal, 2024):
- 1 mg dose: −42.9%
- 4 mg dose: −57.0%
- 8 mg dose: −81.4%
- 12 mg dose: −82.4%
- Placebo: +0.3%
These findings show that retatrutide not only increases weight loss but also dramatically improves metabolic indicators, insulin sensitivity, and lipid metabolism, giving it a promising treatment option for obesity and MASLD (Lilly, 2023) (Sanyal, 2024).
Regulation of Insulinotropic Polypeptides and Related Therapies
The United States Food and Drug Administration (FDA) regulates insulinotropic polypeptide-based medicines (CFR Title 21). Incretin-based medications, such as GLP-1 receptor agonists and DPP-4 inhibitors, must go through rigorous clinical trials to prove their safety, effectiveness, and long-term metabolic advantages. 1. Clinical Trial Phases - Incretin-based medicines, like all new pharmaceuticals, must go through preclinical investigations, then Phase 1, 2, surv...
(All Rights Reserved)